18.07.2012 • News

Saudi Basic Industries Q2 Profits Fall 35%

Saudi Basic Industries Corp (SABIC), the world's biggest petrochemicals group by market value, reported a 35% drop in quarterly profits on Wednesday due to lower prices and production, missing analysts' estimates.

SABIC, which is 70% state-owned, said second quarter net profit was 5.3 billion riyals ($1.41 billion) for the quarter ended June 30, down from 8.1 billion riyals in the prior-year period.

Analysts had forecast, on average, profit of 6.58 billion riyals, in a Reuters poll.

It declared a 2-riyals per share dividend on Wednesday, for the first half of 2012.

The bellwether Middle East conglomerate, which supplies chemicals, industrial polymers, fertilisers and metals globally, blamed the lower profits on a combination of weaker product pricing, the impact of plant maintenance on production and sales volumes as well as higher raw materials costs.

SABIC's profits had fallen in the two previous quarters amid slipping demand in China. But record earnings in the second and third quarter of 2011 helped it achieve a bumper year.

The conglomerate's products are used in a wide variety of industries, from car manufacture to house construction and cheap retail goods making it highly sensitive to movements in the global economy.

SABIC enjoys a comparative advantage over some other chemical producers because much of its feedstock comes from subsidised natural gas supplied by the government.

SABIC said in June it was repaying an 8 billion-riyal Islamic bond, or sukuk, ahead of time.

 

 

 

 

 

 

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.